Sutent 12.5 mg hard capsules clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It compares a combination of two new medicines (Nivolumab and Ipilimumab) with a standard medicine (Sunitinib) to see which works better at helping people live longer and stopping the cancer from growing.
For: Advanced or metastatic renal cell carcinomaGermany · Ireland · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new treatments for advanced kidney cancer. It compares a combination of two drugs, nivolumab and cabozantinib, against a standard treatment, sunitinib, to see which works better and is safer for people who haven't had treatment before.
For: Advanced or Metastatic Renal Cell CarcinomaPoland · Spain · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
This study looks at a new combination of two drugs, pembrolizumab and epacadostat, for advanced kidney cancer. It compares this combination to standard treatments (sunitinib or pazopanib) to see if it works better and is safe for adults.
For: Locally advanced/metastatic renal cell carcinomaSpain